Clinical Trial Update: Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II trial of pralatrexate in Japanese patients with relapsed or refractory peripheral T-cell lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• Pralatrexate (pralatrexate)

Snippet

Sponsor: Mundipharma K.K. | Conditions: Peripheral T-cell Lymphoma | Phase 1, Phase 2 | Status: COMPLETED